← Arcus Biosciences, Inc. (RCUS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Arcus Biosciences, Inc. (RCUS)
Pharmaceutical Preparations · market cap $3.4B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-27 (est.)
Earnings
Pipeline
6
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Arcus Biosciences (RCUS) is a clinical-stage oncology company with a broad pipeline spanning immuno-oncology and targeted therapy across gastrointestinal, renal, lung, and prostate cancers. The company reported two Phase 3 failures in June 2026, leaving it with roughly 4.4 months of cash runway as of mid-July 2026 and a market cap of ~$3.53B. Key near-term catalysts include Phase 3 and Phase 2 data readouts for quemliclustat (est. Q1 2027) and zimberelimab Phase 2 data (est. May 2027).
The catalyst path
- 2026-10-27 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Trial Startimp 3/10
- 2027-01-15 (est.)Phase 3 · Quemliclustatimp 9/10
- 2027-01-15 (est.)Phase 2 · Quemliclustatimp 7/10
- 2027-05-15 (est.)Phase 2 · Zimberelimabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Domvanalimab | Phase 3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma |
| AB680 | Phase 2 | Metastatic Colorectal Cancer |
| Casdatifan | Phase 3 | Metastatic Clear Cell Renal Cell Carcinoma |
| Etrumadenant | Phase 2 | Prostatic Neoplasms, Castration-Resistant |
| Quemliclustat | Phase 3 | Gastrointestinal Tract Malignancies |
| Zimberelimab | Phase 3 | Non Small Cell Lung Cancer |
Price & technical context
3-month
-16.8%
6-month
+15.5%
12-month
+85.5%
52-wk range
$13.35–$31.57
vs 50-day MA
-9.6%
vs 200-day MA
+1.9%
Realized vol
61.6%
Max drawdown
-62.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RCUS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.